Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is West Pharmaceutical Services EV-to-EBITDA?
West Pharmaceutical ServicesWST -1.65%95 EV-to-EBITDA is 29.07 as of Jul. 21, 2026, which is 8% above its 10-year median of 26.94. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $362.80 (Fairly Valued). The stock has 9 warning signs investors should review. Among 510 Medical Devices & Instruments companies, West Pharmaceutical Services ranks worse than 78.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, West Pharmaceutical Services's enterprise value is $24,685 Mil.
West Pharmaceutical Services's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $849 Mil. Therefore, West Pharmaceutical Services's EV-to-EBITDA for today is 29.07.
The historical rank and industry rank for West Pharmaceutical Services's EV-to-EBITDA or its related term are showing as below:
WST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 18.35 Med: 26.94 Max: 48.37
Current: 29.07
During the past 13 years, the highest EV-to-EBITDA of West Pharmaceutical Services was 48.37. The lowest was 18.35. And the median was 26.94.
WST's EV-to-EBITDA is ranked worse than 78.43% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.005
vs WST: 29.07
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
West Pharmaceutical Services (NYSE:WST) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
West Pharmaceutical Services's PE Ratio (TTM) for today is calculated as:
West Pharmaceutical Services's share price for today is $352.32.
West Pharmaceutical Services's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's EV-to-EBITDA falls into.
West Pharmaceutical Services's current Enterprise Value is $24,685 Mil.
West Pharmaceutical Services's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $849 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services (WST) has a EV-to-EBITDA of 29.07 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on West Pharmaceutical Services. This is near median its historical median of 26.94. Over the past decade, West Pharmaceutical Services' EV-to-EBITDA has ranged from 18.35 to 48.37. According to the industry distribution chart, West Pharmaceutical Services ranks #400 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 78.4%.
Is West Pharmaceutical Services' EV-to-EBITDA too high?
West Pharmaceutical Services' current EV-to-EBITDA of 29.07 is near median its 10-year median of 26.94. Over the past 10 years, this metric has ranged from a low of 18.35 to a high of 48.37. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.01. West Pharmaceutical Services' value of 29.07 is 107.6% above this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #400 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' EV-to-EBITDA compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #400 out of 510 companies for EV-to-EBITDA. This places West Pharmaceutical Services in the lower half of its industry. The industry median EV-to-EBITDA is 14.01. West Pharmaceutical Services' value of 29.07 is 107.6% above this benchmark. Historically, West Pharmaceutical Services' own EV-to-EBITDA has ranged from 18.35 to 48.37 over the past decade. While the company's 10-year median is 26.94 vs. the industry median of 14.01, West Pharmaceutical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.01, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current EV-to-EBITDA of 29.07 is 107.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on West Pharmaceutical Services. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current EV-to-EBITDA is 29.07, which is near median its own 10-year median of 26.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $362.80, compared to a current price of $352.32 — trading 2.9% below its estimated fair value. The current EV-to-EBITDA is 29.07, which is near median its 10-year median of 26.94 and 107.6% above the Medical Devices & Instruments industry median of 14.01. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current EV-to-EBITDA is 29.07 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $352.32 is trading 2.9% below its estimated GF Value™ of $362.80.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
EV-to-EBITDA: 29.07 (near median its 10-year median of 26.94)
GF Value™: $362.80 vs. price of $352.32 (2.9% below fair value)
Industry Position: 107.6% above the Medical Devices & Instruments median (#400 of 510)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score
Get the complete analysis for WST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
